ERBB2 and breast cancer: However, as the overexpression of this tyrosine kinase (TK) receptor does not occur under normal physiological conditions [3], on the other hand, it has allowed the development of anti-HER2 targeted agents that have dramatically improved the survival rate of patients suffering from HER2-positive (HER2+) BC [2].